Biomarker Development in Sturge-Weber Syndrome — Pilot  

Sturge-Weber Syndrome Clinical Trial

Official title: Establishing Reliability for Quantitative EEG, Transcranial Doppler, Behavioral Outcomes and Optical Coherence Tomography in SWS: The Next Step Toward Biomarker Development

Status Completed

Clinical Trial Summary

This is a study of 40 individuals with Sturge-Weber Syndrome (SWS) brain and/or eye involvement. It will examine the test-retest reliability of the following clinical tests:

1. Quantitative EEG

2. Transcranial Doppler

3. Medical Rehabilitation Scales

4. Optical Coherence Tomography

Clinical Trial Description

Sturge-Weber Syndrome (SWS) is a rare disorder presenting at birth with a facial port-wine birthmark and later in infancy with seizures and strokes that result in weakness on one side of the body, cognitive disabilities, glaucoma, and visual field deficits. Approximately 10-50% of infants born with a facial port-wine birthmark on the upper part of the face will also have SWS brain and/or eye involvement. Early detection and treatment of the disease is necessary to improve an SWS patient's outcome, and early biological indicators need to be discovered to make this possible. We believe the following tests can serve as non-invasive biomarkers to improve early diagnosis, monitor response to treatment, and to predict outcome:

1. Quantitative EEG

2. Transcranial Doppler

3. Medical Rehabilitation Scales

4. Optical Coherence Tomography The first step of this process is to determine how much the results of these tests vary between individual tests. ;

Related Conditions & MeSH terms

• Brain Stem Infarctions
• Sturge-Weber Syndrome
• Syndrome

• NCT number: NCT01345305
• Study type: Observational
• Source: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
• Status: Completed
• Start date: July 2010
• Completion date: November 2012